Innate Lymphoid Cells are the Predominant Source of Interleukin-17A During the Early Pathogenesis of Acute Respiratory Distress Syndrome


Published in:
American Journal of Respiratory and Critical Care Medicine

Document Version:
Peer reviewed version

Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal

Publisher rights
Copyright © 2015 by the American Thoracic Society
Originally Published in: Muir et al., Innate lymphoid cells are the predominant source of interleukin-17A during the early pathogenesis of acute respiratory distress syndrome, American Journal of Respiratory and Critical Care Medicine, 2015;Volume 193, Issue 4: Pages 407-416.
DOI: 10.1164/rccm.201410-1782OC
The final publication is available at http://www.atsjournals.org/doi/10.1164/rccm.201410-1782OC#.Vop6lvmLRhE

General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Innate lymphoid cells are the predominant source of interleukin-17A during the early pathogenesis of acute respiratory distress syndrome

Roshell Muir1†, Megan Osbourn1†, Alice V. Dubois1, Emma Doran1, Donna M Small1, Avril Monahan1, Cecilia M. O'Kane1, Katherine McAllister1, Denise C. Fitzgerald1, Adrien Kissenpfennig1, Daniel F. McAuley1,2, and Rebecca J. Ingram1*.

1Centre for Infection and Immunity, Queen’s University Belfast, 97 Lisburn Road, Belfast, UK. 2Regional Intensive Care Unit, Royal Victoria Hospital, Belfast, UK

†These authors contributed equally to this work.

Concept and design: RJI, DFM, CO’K, RM. Laboratory analysis and interpretation: RM, MO, KM, AM AVD, ED, DMS. Manuscript preparation and significant intellectual input: RJI, DFM, CO’K, RM, AVD, DF, AK.

*Corresponding author; Dr. Rebecca Ingram, Centre for Infection and Immunity, Queen’s University Belfast, 97 Lisburn Road, Belfast BT9 7AE, UK. Tel: +4428 9097 2090; Fax: +4428 9097 2671; E-mail address: b.ingram@qub.ac.uk.1

Running title; ILCs are the main source of IL-17 in ARDS

Descriptor number; 4.1 ALI/ARDS: Biological Mechanisms

1 This work was funded by the Dina Korner Endowment Fund, Queen’s University Belfast. R Muir and M Osbourn were supported by Department of Education and Learning (Northern Ireland) PhD studentships.
Abstract

Rationale: IL-17A is purported to help drive early pathogenesis in acute respiratory distress syndrome (ARDS) by enhancing neutrophil recruitment. Whilst IL-17A is the archetypal cytokine of T helper (Th)17 cells, it is produced by a number of lymphocytes, the source during ARDS being unknown.

Objectives: To identify the cellular source and the role of IL17A in the early phase of lung injury

Methods: Lung injury was induced in WT (C57BL/6) and IL-17 KO mice with aerosolised LPS (100 µg) or *Pseudomonas aeruginosa* infection. Detailed phenotyping of the cells expressing RORγt, the transcriptional regulator of IL-17 production, in the mouse lung at 24 hours was carried out by flow cytometry.

Measurement and Main Results: A 100-fold reduction in neutrophil infiltration was observed in the lungs of the IL-17A KO compared to wild type (WT) mice. The majority of RORγt+ cells in the mouse lung were the recently identified type 3 innate lymphoid cells (ILC3). Detailed characterisation revealed these pulmonary ILC3s (pILC3s) to be discrete from those described in the gut. The critical role of these cells was verified by inducing injury in Rag2 KO mice which lack T cells but retain ILCs. No amelioration of pathology was observed in the Rag2 KO mice.

Conclusions: IL-17 is rapidly produced during lung injury and significantly contributes to early immunopathogenesis. This is orchestrated largely by a distinct population of pILC3 cells. Modulation of pILC3s’ activity may potentiate early control of the inflammatory dysregulation seen in ARDS, opening up new therapeutic targets.

Abstract word count 247

Key Words: ARDS, acute lung injury, IL-17, lymphocyte, ILC3, pILC
Introduction

Acute respiratory distress syndrome (ARDS) is characterised by a dysregulated inflammatory response and neutrophil infiltration (1). Murine models of lung injury have demonstrated that lymphocytes rapidly influx into the lung during the early phase (exudative phase) (2–5) and the lymphocyte derived pro-inflammatory cytokine interleukin (IL)-17A is believed to contribute to pathogenesis by augmenting neutrophil recruitment (6–9). IL-17 is known to promote the production of various other inflammatory mediators including IL-6, IL-8, tumour necrosis factor (TNF)-α, IL-1β, granulocyte-colony stimulating factor (G-CSF), monocyte chemoattractant protein (MCP)-1 (10). It is also known to directly drive the production of macrophage inflammatory protein (MIP)-2 (11).

Differentiation of lymphocytes towards a type 17 programme is dependent on the expression of the transcription factor RORγt (12, 13). Although IL-17 was first described as the signature cytokine of CD4+T helper (Th)17 cells it is now known to also be secreted by cytotoxic CD8+T (Tc) cells, gamma delta (γδ) T cells, invariant natural killer (iNK)T cells and CD3- natural killer (NK) cells (14). Recently, innate lymphoid cells (ILCs) have emerged as a key producer of IL-17 (15).

ILCs represent a family of developmentally related innate cells that are able to produce a broad range of cytokines. They have been ascribed a role in the defence of mucosal surfaces, as well as in tissue homeostasis and repair following infection and inflammation (16). ILCs require the common cytokine-receptor γ-chain (cγ) signalling (17) and IL-7R expression for their development and maintenance (18). Recently, a uniform nomenclature has been proposed to define sub-populations of
ILCs based on phenotypical and functional characteristics (19). RORγt⁺ ILCs, which express IL-17A, have been denoted as ILC3s. The essential role of ILC3s in both protection and immunopathology within the gut mucosa is now well recognised (16); however, their impact at other mucosal sites has not been reported in detail.

Whilst it has been supposed that IL-17A in the lung during the exudative phase of ARDS is CD4⁺ T cell derived (6–8), a comprehensive examination of the cellular source of this cytokine has not been performed. Thus, the aim of this study was both to substantiate the role of IL-17A in the early pathogenesis of lung injury and determine the source of this cytokine. We confirmed the critical role of IL-17A in neutrophil recruitment in IL-17 knock out (KO) mice and demonstrated that ILC3s represent the greatest proportion of the RORγt⁺ cells within the lung during the acute phase of lipopolysaccharide (LPS)-induced lung injury. The ability of pulmonary ILC3s to drive neutrophil recruitment was confirmed in Rag2 KO mice, which lack all adaptive lymphocytes, including T cells. This is the first reported demonstration of ILC3s contributing to pathogenesis within the lung.

Some of the results of these studies have been previously reported in the form of an abstract(s) (20–22).
Methods

Additional methodological details available online.

Animals

Sex- and age- (6-14 weeks) matched C57BL/6 wild-type (WT) mice and IL-17A KO mice were bred in house. Recombinase activating gene 2-deficient knock out (Rag2 KO) and Rag2 and the common cytokine receptor γ chain (cγ Rag2 DKO) mice were obtained from MRC National Institute for Medical Research, UK.

Induction of lung injury in mice.

Lung injury was induced in mice by the administration of either *E. coli* LPS (100 µg) (Sigma, UK- serotype 0111:B4) or $5 \times 10^6$ CFUs of *Pseudomonas aeruginosa*. Mice were anaesthetised and, unless otherwise stated, all mice were administered LPS orotracheally (o.t.). Mice were intubated using a high-pressure syringe and MicroSprayer aerosoliser (Penn-Century. Inc. Wyndmoor, PA) and LPS or a saline control (50 µl) delivered into the lung. For intra-nasal (i.n) administration, 20 µl of LPS, bacteria or saline control were applied drop wise to the animal’s nose and were inhaled by normal respiration. Mice were culled at 24 h post induction, unless otherwise stated. To calculate the lung indices, a measure of pulmonary inflammation, the following equation was used; Lung index = (lung weight/body weight experimental) / (lung weight/body weight control).
**Lung Histology**

Lungs were excised and fixed in 10 % formaldehyde and 3 µm sections were cut, stained with Haematoxylin and eosin (H&E) and mounted. A researcher blinded to the groups scored the damage to the lung (23).

**Quantification of inflammatory markers within the lung.**

Bronchoalveolar lavage fluid (BAL) was obtained by the instillation of 600 µl of PBS. Lung homogenate was prepared by homogenising perfused lung in 500 µl of PBS with a mechanical homogeniser (VWR, UK). The levels of IL-17A, IL-6, IL-23p19 (eBioscience, UK), keratinocyte-derived chemokine (KC), IL-2 (R&D Systems, UK) and MIP-2 (Preprotech, USA) were determined by ELISA. Myeloperoxidase (MPO) activity was measured using amplifu red (Sigma-Aldrich, UK). Protein was quantified using Pierce BCA protein assay (Thermo Scientific, USA). Assays were read on a spectrophotometer (BioTek, USA).

**Isolation and preparation of lung cells**

Perfused lungs were harvested into Iscoves’s Modified Dulbecco’s Medium (IMDM) (Gibco, UK) supplemented with 10 % fetal calf serum (FCS) (Source Bioscience, UK) and 1 % penicillin/streptomycin (PAA, UK). The lung was finely minced and incubated at 37°C with 1 mg/mL Collagenase D and 200 µg/mL DNase 1 (Roche, Germany). The samples were then passed through a 70 µm cell strainer (Becton Dickinson, UK) to obtain a single cell suspension.
**Ex vivo cell stimulation**

A single cell suspension was plated in IMDM media supplemented with 10 % FCS and 1 % P/S, and stimulated with IL-23 (50 ng/ml), IL-7 (10 ng/ml) (Milteni, UK) or IL-2 (10 ng/ml) (Dynax, USA) or combinations of these cytokines. The cells were incubated at 37°C with 5 % CO₂. At specific time points (4, 24, 48 and 72 h), the cell culture supernatant (750 µL) was removed and stored at -80°C until analysis for IL-17A by ELISA. At 72 h the cells were restimulated with a commercial stimulation cocktail (eBioscience, UK), to induce IL-17 production, and protein transport inhibitor cocktail (eBioscience, UK), to prevent cellular secretion of this IL-17. After 5 h, the cells were analysed for the presence of intracellular IL-17, in combination with cell surface markers to identify specific cellular populations, using flow cytometry.

**Flow cytometry**

Cells were washed in FACS buffer (PBS, 2 % FCS) and the cell pellets were blocked for 15 minutes at room temperature with anti-CD16/CD32 (eBioscience, UK). The cells were surface stained with specific antibodies (detailed in the supplementary methods), or an appropriate isotype control, to delineate the cellular populations (Figure E1). The cells were washed to remove any unbounded antibody and fixed/permeabilised (eBioscience, UK) overnight. Intracellular antibodies targeting RORγt (eBioscience, UK), IL-17A or an appropriate isotype control were applied. After incubation cells were washed, fixed and acquired on a FACSCanto II (Becton Dickinson, UK). Data analysis was performed using FlowJo software (FlowJo Inc, OR, USA)
Quantitative Real Time PCR

Lung injury was induced with LPS in WT, Rag2 KO and cγ Rag2 DKO mice and the lungs were collected at 4 h. RNA was extracted using TRIzol reagent (Life Technologies, UK), transcription and quantitative PCR were conducted using the Superscript III Platinum One-Step kit (Life technologies, UK), with TaqMan probes on a Stratagene MX3005P real-time PCR machine (Agilent Technologies, Germany). The fold change in IL-17A gene expression levels, relative to a PBS-treated control, and normalised to the housekeeping gene YWHAZ, was calculated using the $2^{-\Delta\Delta CT}$ method (24).

Statistical Analyses

Nonparametric data was normalised prior to analysis, results were compared using Student's t-test or one-way ANOVA. The exception to this is the real-time PCR analysis in which a Kruskal-Wallis test was used. Graphic data represents the mean (± SEM).
Results

*IL-17A plays a significant role in recruiting neutrophils to the lung*

The role of IL-17 in the early immunopathogenesis of acute lung injury was investigated by comparing the responses of WT (C57BL/6) or IL-17A KO mice in a murine model of LPS induce lung injury. Histological examination of the lungs demonstrated that, in WT mice LPS treatment resulted in diffuse cellular infiltration, whilst in the IL-17 KO lungs there were only patchy foci of inflammation (Figure 1A). Scoring of the lung damage observed histologically (23) revealed that there was significantly less injury in the IL-17 KO mice (p = 0.04) (Figure 1B). No injury was observed in the saline treated controls of either strain (Figures 1A & B). There was decreased pulmonary inflammation in the IL-17 KO mice as illustrated by a significant reduction in the lung index (p = 0.009) (Figure 1C). Reduced protein within the BAL (p = 0.04) (Figure 1D) indicates a reduction in oedema in the IL-17 KO mice. A significant, 100-fold reduction in the numbers of neutrophils recruited into the lungs was observed in IL-17A KO mice in comparison to WT mice (p = 0.03) (Figure 1E). There was also a significant reduction in myeloperoxidase (MPO) levels (p = 0.05) (Figure 1F), a marker of neutrophil activity (25).

IL-6 was significantly lower in the IL-17 KO mice (p = 0.04) (Figure 1G) than in the WT controls. Levels of KC, the murine homolog of IL-8, were not significantly reduced (p = 0.09) (Figure 1H), however, levels of the IL-17 dependant neutrophil chemoattractant MIP-2 (11) were significantly reduced (p = 0.01) (Figure 1I).

IL-17 driven recruitment of neutrophils into the lung was also apparent when bacterial pneumonia was used to induce lung injury. There was a significant reduction in the
percentage of neutrophils detected within the BAL (p = 0.005) (Figure 2A). Again, demonstrating the downstream effects of IL-17, a significant reduction in the levels of MIP-2 (p = 0.04) were observed (Figure 2B). The diminished neutrophilia within the lung resulted in a trend towards reduced damage, indicated by protein levels in the BAL (p = 0.052) (Figure 2C), and disease severity (IL-6 p = 0.1) (Figure 2D). There was no significant difference in the bacterial burden within the lungs of the WT and IL-17 KO mice (data not shown).

*ILCs are the predominant RORγt* cells detected within the lung during the acute phase of lung injury.*

To establish the cellular source of the IL-17, injury was induced in C57BL/6 mice and lung cells were harvested 24 hours post administration. The expression of RORγt, was determined using flow cytometry. LPS administration resulted in a significant increase in the number of RORγt+ cells (p = 0.001) within the lung, in comparison to PBS treated control mice (Figure 3A). When the phenotype of the gated RORγt+ cells was examined, the frequency of NKT, NK and γδ T RORγt+ cells was low (Figure 3B & E1). The lung leukocyte RORγt+ population consisted predominantly of ILC (28.6 % ± 5.9) and αβ T cells (30.9 % ± 10.1) (Figure 3B & E1). The αβ T cells were equally divided between CD4+ (Th17) and CD8+ (Tc17) cells (p = 0.43) (Figure. 3B & E1). To further verify IL-17 production in the RORγt+ cells, injury was induced and the lungs were harvested. The cells were rested and then restimulated *ex-vivo* to induce a further burst of IL-17 production. Golgi block prevented cellular release of the IL-17, thus allowing the identification of IL-17+ cells. Both RORγt+ ILCs and CD4+ T cells produced IL-17A but this was not observed in CD8+ cells (Figure 3C).
A significant augmentation of the ILC3 population was observed in the lung post-LPS exposure (p = 0.01) (Figure 4A) and these cells far outnumbered the Th17 cells detected in the lung (p = 0.009) (Figure 4B). However, no significant difference in the median fluorescence intensity of IL-17A expression, an indicator of production per cell, was detected between the CD4+ cells and ILCs stimulated ex vivo (p = 0.9) (Figure 4C), indicating ILC3s are the predominant source of IL-17.

To further verify that ILC3s are the critical source of IL-17, RNA expression levels were examined in WT, Rag2 KO (lacking T cells, but retaining ILCs) and γδ Rag2 DKO (lacking both T cells and ILCs) mice using quantitative real-time PCR. In the γδ Rag2 mice in which both adaptive and innate lymphocytes are absent (γδ Rag2 DKO) IL-17A (Figure 5A) was not detected. When ILCs are present (Rag2 KO) mice, IL-17 expression was not significantly different from the WT controls (p = 0.4) (Figure 5A). Furthermore, there was no significant difference in the lung index (p = 0.5) (Figure 5B) or IL-17 induced cytokine MIP-2 (p = 0.2) (Figure 5C), in Rag2 KO mice compared to WT controls. The Rag2 KO mice showed elevated levels of neutrophil infiltration (p = 0.02), KC levels (p = 0.002) and a trend towards increased IL-6 (p = 0.06) following LPS induced lung injury.

*IL-17A production in lung lymphocytes is induced by IL-23 and amplified by IL-2.*

IL-23 is known to drive IL-17 production (14), whilst IL-2 and IL-7 both utilise the cytokine-receptor common γ-chain known to be involved in ILC signalling (17). To examine the regulation of IL-17 production in ILC3s, cells were harvested from the lungs of LPS exposed mice and cultured in the presence of rIL-23, rIL-2 and rIL-7 or combinations thereof. The levels of IL-17A in the cell culture supernatant at 4, 24, 48
and 72 h were quantified by ELISA. IL-17A production continued to increase up to 72 h (Figure 6A). No significant difference was observed in IL-17A levels when the cells were stimulated with all three cytokines or with just IL-23 and IL-2 (p = 0.94) (Figure 6B), suggesting there is little role for IL-7 in induction of IL-17A production by ILC3s in this model. Whilst IL-23 alone induced IL-17A release, this was significantly augmented when IL-2 was added (p = 0.004) (Figure 6B). To verify that the IL-2 was not preferentially driving T cell production of IL-17A, intracellular flow cytometry was used to demonstrate IL-17A production by the ILC3s after 72 h stimulation. No differences were observed in the contribution of T cells to the IL-17A production when the cells were stimulated with IL-2 compared to IL-23 (Figure 6C). When ILC3s were cultured with IL-2 there was a significant increase in the percentage of cells expressing the receptor for IL-23 (p = 0.03) (Figure 6D). Following the induction of acute lung injury in vivo, elevated levels of IL-23p19 were detected in murine BAL (p = 0.04) (Figure 6E). A significant elevation in IL-2 levels is observed in the mice at 12 h in LPS-treated mice compared to control-treated animals (p = 0.02) (Figure 6F).

**Phenotypic analysis of the lung ILCs**

To further phenotype the RORγt+ ILCs in the lung during LPS induced lung injury, a detailed characterisation of the expression of a number of surface receptors was carried out. We identified a population of cells within the lung during the exudative phase of lung injury that were defined as ILC3 based on the lack of expression of lineage markers (Lin−) and expression of CD45 and RORγt (Figure E2A). The expression of ILC surface markers on these cells was characterised (Figure E2B-G & Table 1). The most abundant RORγt+ ILCs characterised resembled the NCR− ILC3s (58 %) described in the gut (12), with the exception that the cells detected in the lung
were CD117 (c-KIT) positive. The second most frequent cell type had the surface marker expression profile described for LTi cells (21 %) (26). There was also a small population of NCR$^{+}$ ILC3s (3 %) identified (27). For both the LTi cells and NCR$^{+}$ ILC3s there was no disparity in the expression of surface markers compared to cells from the gut. All three populations of RORγt$^{+}$ ILCs also expressed chemokine receptor 6 (CCR6).

**Discussion**

Neutrophils play an essential role in the innate immune response during infection and inflammation; and their infiltration into the airspace is a hallmark feature of ARDS (1). It has been suggested that the proinflammatory cytokine IL-17A plays a role in neutrophil recruitment within the lung during lung injury (6–8). Utilising an IL-17 KO mouse model (28), the pivotal role of IL-17A in early neutrophil recruitment into the lung following LPS exposure was confirmed.

During lung injury the IL-17 KO mice also showed reduced levels of damage using a number of the criteria set out by Matute-Bello et al (23). There was also abrogation of IL-6 production, a surrogate marker of disease severity in murine models (29, 30). MIP-2 is a potent neutrophil chemoattractant and has previously been shown to play a key role in ARDS (31). Expression of MIP-2 is known to be driven by IL-17 via the MAPK pathway (11), offering an insight into the mechanism by which IL-17 is able to exert it’s effects during early immunopathogenesis of lung injury. Similar results were observed when lung injury was induced with a clinically relevant bacterial pneumonia model. There was a significant reduction in the percentage of neutrophils detected within the BAL of the IL-17 KO mice, and reduced MIP-2 levels. This is consistent
with findings using the caecal ligation puncture (CLP) model of polymicrobial sepsis, where IL-17 neutralisation led to a decrease in pro-inflammatory cytokines (TNFα, IL-1β and IL-6); and surprisingly, a decrease in bacteraemia (32). This suggests that IL-17 neutralisation may have therapeutic potential for the treatment of ARDS, particularly given anti-IL-17 therapy has shown efficacious in experimental models of sepsis (33).

It has been purported that the source of IL-17A in ARDS is CD4+ T cells; however there is lack of detailed analysis of the specific cellular source. Differentiation of lymphocytes towards a type 17 programme is dependent on the expression of the master regulator transcription factor RORγt (14). Therefore, we phenotyped cells expressing the transcription factor RORγt within the mouse lung during the early phase of lung injury. It was demonstrated that ILCs represented the largest proportions of RORγt+ cells within the lung during the early pathogenesis. Whilst both CD4+ and CD8+ αβ T express RORγt, CD8+ cells did not produce IL-17A upon ex-vivo restimulation. This suggests that although predisposed to producing IL-17, Tc17s do not specifically produce IL-17A in this model. It has previously been suggested that, in the presence of Th17 cells, Tc17 cells have reduced functionality due to IL-2 released by CD4+ T cells (34). This may explain the observation that Tc17 cells contribute little to IL-17 production in this setting.

It was shown that ILC3s were the predominant IL-17A producing cells in the lung during LPS induced lung injury. This conclusion was based on the detection of significantly higher absolute numbers of RORγt+ pILC3s compared to CD4+ T cells, but no difference in the median fluorescence intensity, an estimation of the levels of
IL-17A expression per cell, in CD4$^+$ T cells and ILC3s. To further verify the critical role of ILCs in lung injury, we examined the relative expression of IL-17 using quantitative real-time PCR. Although there was a reduction in the relative expression in the Rag2 KO mice, which lack T cells, it was only when ILCs were also absent (cγRag2 DKO) that a significant reduction compared to the WT animals was observed. The proposal of ILC3s as the main source of IL-17A is corroborated by previous studies which have demonstrated that IL-17- induced neutrophil infiltration occurs in SCID mice lacking T cells (6) and the majority of IL-17$^+$ cells within the BAL are CD3$^-$ (8, 9). This is mirrored in the oral mucosa, where ILC3s have been shown to be the predominant source of IL-17 in response to Candida infection (35). There were significantly higher numbers of neutrophils and KC levels detected in the lungs of Rag2 KO mice compared to WT controls. This may indicate that the ILC3 cells are normally restrained by Tregs or Bregs, both of which are absent in the Rag2 KO mice. Whilst ILCs predominated the early response during acute lung injury, this appears to be superseded at later time points by an adaptive αβ T cell response (36).

ILCs are known to be dependent on the common- receptor γ chain of the IL-2 family of cytokines for their development (17) and require signalling through the IL-7 receptor subunit alpha (IL-7Rα) (18). Additionally, IL-23 has also been shown to direct and maintain IL-17 production in ILCs (26). Investigation of the role of these cytokines in IL-17A production by ILC3 from LPS primed lungs demonstrated that there is little involvement of IL-7 in this model, despite these cells expressing high levels of IL-7Rα (CD127). In contrast, IL-23 was shown to drive IL-17A production and this was significantly increased by IL-2. This IL-2 augmentation of IL-17A levels could be seen as counter intuitive, given reports that IL-2 inhibits Th17 differentiation.
(37). However, cytokines are known to have a differential effect on developing versus committed Th17 cells (38), and there have been reports of IL-2 expansion of differentiated Th17 cells (39). Furthermore, IL-2 enhances IL-33 driven IL-9 production in ILC2 cells (40). Incubation with IL-2 increased the percentage of ILC3s expressing IL-23 receptor. During the induction of lung injury there was an early peak of IL-2 detected in the murine BAL, presumably this primes the cells for optimal response to IL-23 and subsequent IL-17 production. Whilst the synergistic effects of IL-6, IL-23 and low concentrations of TGF-β on the expression of IL-23 receptor have been characterised (41), its upregulation by IL-2 has not been previously described.

A uniform nomenclature has been proposed in order to clarify ILC populations based on phenotypical and functional characteristics (19). The group 3 ILCs produce IL-17A, with LTi cells being the prototypical cells in this group (26). Other distinct subsets have been characterised, those expressing the natural killer cell receptor (NCR) NKp46 are denoted NCR+ ILC3s and there is also a population that lack NCR, like LTi cells, but are CD4− (19). We examined the expression of a number of cell markers that have previously been used to define ILC populations. Within the lung the ILCs identified were largely comparable to those previously defined in the gut (27, 42). However, there was some variance in the expression of surface markers; therefore we have termed the unique population identified within the inflamed lung as pulmonary ILC3s (pILC3s).

In T cells, the expression of CCR6 is limited to Th17 and Treg cells (43). ILC3s in the gut have been shown to express CCR6 (44). We have demonstrated that pILC3s
within the lung also expressed CCR6, it therefore seems likely that, as with T cells, CCR6 mediates homing of RORγt⁺ ILC3s into tissues and inflammatory sites (43).

Previous studies have demonstrated that ILC2s interact with the lung epithelium and are involved in both repair and pathogenesis (45–47). In contrast, ILC3s had previously only been described playing a protective role in the lung. They function in the repair of the lung following influenza A infection (48) and protect against secondary bacterial infection (49). To the best of our knowledge, this is the first report of ILC3s driving inflammation within the lung and it is clear that an inappropriate response is capable of resulting in immunopathology in the lung, as has been previously described in the gut (12).

In conclusion, the significant decrease in neutrophil infiltration in IL-17KO mice in an LPS-induced model of lung injury confirms the previously surmised key role of this cytokine in the early immunopathogenesis. Most notably, it was demonstrated that the predominant source of this proinflammatory cytokine during lung injury was the innate immune system. Recognition of the role of pILC3s in initiating acute lung inflammation may offer new therapeutic opportunities as modulation of ILCs’ function may allow early control of inflammatory dysregulation.
Acknowledgements
The authors would like to thank Dr Yoichiro Iwakura (IL-17 KO mice), Dr Mark Wilson (Rag2 KO and cγ Rag2 DKO mice) and Prof Scott Bell (PA01 P. aeruginosa) for kindly providing resources utilised within this study.

Disclosure
Drs. Muir & Osbourn reports other from Department of Education and Learning (Northern Ireland), during the conduct of the study. Dr. McAuley reports personal fees from GlaxoSmithKline, personal fees from Peptinnovate, outside the submitted work; In addition, Dr. McAuley has a patent application pending to Queen's University Belfast. Dr. Ingram reports grants from Queen's University Belfast, during the conduct of the study.
References


Legends

**TABLE 1. Phenotypic markers of lung innate lymphoid cells.** Lin⁺ CD45⁺ RORγt⁺ lung ILC3s were analysed by flow cytometry and the expression of cell surface markers associated with ILC subsets were characterised (Figure E2); 3 discrete populations were identified. The data is representative of three independent experiments, each experiment utilised n = 3 mice pooled. LTi, lymphoid tissue inducer cell; NCR, natural cytotoxicity receptor; SCA-1, stem cell antigen-1; NK, natural killer.

**FIGURE 1. IL-17 plays a key role in the recruitment of neutrophils during the early pathogenesis of LPS induced lung injury.** Following (24 h) LPS administration there was a difference in the levels of injury detected within the lungs of WT C57BL/6 or IL-17KO mice. Representative images from H&E stained lungs (x 20 magnification) are shown (A) along with scoring based on neutrophils in the alveolar space, neutrophils in the interstitial space, hyaline membranes, proteinaceous debris filling the airspaces and alveolar septal thickening (23) (n = 3 mice per treatment) (B). The lung index (Lung index = (lung weight/body weight experimental) / (lung weight/body weight control)), indicative of pulmonary inflammation, was calculated (n = 6 per group) (C). BAL was collected and the levels of protein detected (n = 18-20 per group) (D). Neutrophils (Ly6-G⁺ CD11b⁺) were analysed by flow cytometry and the absolute numbers of BAL neutrophils calculated (n = 6-10 per group) (E). Levels of MPO activity (F), IL-6 (G) KC (H) and MIP-2 (I) were measured in the BAL fluid (n=10-20 per group). *p < 0.05.
FIGURE 2. Reduced neutrophil recruitment is observed in IL-17 KO mice following bacterial pneumonia induced lung injury. WT C57BL/6 or IL-17 KO mice were inoculated intranasally with 5 x 10⁶ CFUs of *Pseudomonas aeruginosa* (PA01), BAL was collected 24 h post inoculation and the percentage of neutrophils (Ly6-G⁺ CD11b⁺) analysed by flow cytometry (A). Total protein (B), IL-6 (C) and MIP-2 (D) levels were quantified (n = 8 per strain). *p < 0.05.

FIGURE 3. RORγt⁺ lymphocytes are recruited to the lung of mice during LPS-induced lung injury. Lung cells were harvested 24 h post LPS administration and flow cytometry was performed. The absolute number of RORγt⁺ lung cells was calculated using the total lung cell count and the percentage of RORγt⁺ cells (A). The RORγt⁺ cells within the lung were phenotyped and the percentage of NK cells (CD3⁻ NK1.1⁺), NKT cells (CD3⁺ NK1.1⁺), Th17 cells (CD3⁺ NK1.1⁻ CD4⁺), Tc17 cells (CD3⁺ NK1.1⁻ CD8⁺), γδ T cells (γδ TCR⁺) and ILCs (CD45⁺ Lin⁻ NK1.1⁻ γδ TCR⁻) determined (B). The *in vivo* LPS primed cells were cultured and restimulated to increase IL-17 production, in the presence of a golgi block to prevent cytokine secretion. Intracellular cytokine staining, using either anti-IL-17A or an isotype control was performed. The isotype control, which demonstrates the levels of non-specific binding, was used to position the positive gate and the production of IL-17A in RORγt⁺ cells (black) and RORγt⁻ cells (grey) was plotted against side scatter (SSC) assessed (C) (n = 3 mice pooled, in three independent experiments). *p < 0.05.
FIGURE 4. There are significantly more RORγt+ ILCs than Th17 cells in the lung during the early stages of LPS induced lung injury. LPS, or saline control, was administered o.t to C57BL/6 mice. Lungs were harvested after 24 h and flow cytometry performed. LPS administration resulted in a significant increase in the absolute numbers of RORγt+ ILC3s within the lung (A). Higher numbers of ILC3s than Th17 (CD4+) T cells were detected following LPS administration (B). When these cells were restimulated ex vivo there was no difference in the median fluorescent intensity (MFI), an indication of the amount of expression per cell, of IL-17A expression between ILC3s and Th17 cells (C) (n=3 mice/group pooled, three independent experiments performed). * p < 0.05.

FIGURE 5. Induction of lung injury in mice lacking T cells, confirms the critical role of ILC in IL-17 production and neutrophil recruitment. The lung of WT, Rag2 KO (lacking T cells) and cγ Rag2 DKO (lacking both T cells and ILCs) were harvested 4 h post LPS exposure. The expression of IL-17A was analysed by real-time PCR; the data were normalised using the house-keeping gene YWHAZ and the 2^−ΔΔCT used to analyse the expression levels relative to a PBS control (WT and Rag2 KO n = 13 per strain, cγ Rag2 DKO n = 6) (A). Lung injury was induced in WT and Rag2 KO mice by i.n administration of LPS; after 24 h the lungs were harvested and weighed to calculate the lung index (B). The lungs were homogenised and the levels of MIP-2 (C), the total number of neutrophils (D), IL-6 (E), and KC (F) concentration calculated (n = 6 per strain). * p < 0.05.
FIGURE 6. IL-23 induces IL-17A production in lung lymphocytes which is amplified in the presence of IL-2. Cells harvested from the lungs of LPS treated mice were incubated ex vivo with rIL-23, rIL-2 and rIL-7 or combinations of these cytokines. The cell culture supernatants were sampled at 4, 24, 48, 72 h and the level of IL-17A quantified (A) (n=3 mice pooled, 6 replicates). Cells were cultured with all possible combinations of cytokines for 72 h and the levels of IL-17A determined (B) (n=3 mice pooled, repeated 3 times), *p < 0.05. Flow cytometry was used to stain intracellular IL-17A levels following stimulation with IL-2 and IL-23 and to determine the percentage of IL-17+ cells which were ILC3s (C). The percentage of ILC3s expressing IL-23R on their surface following culture with IL-2 was analysed by flow cytometry (D) (n = 3 mice pooled, in triplicate). Following the induction of acute lung injury in C57BL/6 mice the levels of IL-23p19 within the BAL at 24 h was assessed (E) (n = 10-16/group, *p < 0.05), IL-2 levels in the BAL were quantified at 8, 12 and 24 h post LPS exposure (F) (LPS n = 4 per time point, PBS n = 3 per time point, *p < 0.05).
TABLE 1

<table>
<thead>
<tr>
<th>ILC Group 3 subset</th>
<th>pILC3</th>
<th>LTI cells</th>
<th>NCR+ ILC3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Marker</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lin− CD45+ RORγt+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CD90 (Thy1)</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Sca1 (Ly6A)</td>
<td>+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>NKp46 (NCR)</td>
<td>-</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>CD117 (c-Kit)</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CD127 (IL-7Rα)</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>CD4</td>
<td>-</td>
<td>high</td>
<td>low</td>
</tr>
<tr>
<td>CCR6</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Percentage detected</td>
<td>58</td>
<td>21</td>
<td>3</td>
</tr>
<tr>
<td>Reference</td>
<td>This study</td>
<td>(19, 24)</td>
<td>(19, 25)</td>
</tr>
</tbody>
</table>
Figure 1
Figure 2

A) % neutrophils in BAL

B) Protein (mg/ml)

C) IL-8 (ng/ml)

D) MIP-2 (ng/ml)
Innate lymphoid cells are the predominant source of interleukin-17A during the early pathogenesis of acute respiratory distress syndrome

Roshell Muir\textsuperscript{1†}, Megan Osbourn\textsuperscript{1†}, Alice V. Dubois\textsuperscript{1}, Emma Doran\textsuperscript{1}, Donna M. Small\textsuperscript{1}, Avril Monahan\textsuperscript{1}, Cecilia M. O’Kane\textsuperscript{1}, Katherine McAllister\textsuperscript{1}, Denise C. Fitzgerald\textsuperscript{1}, Adrien Kissenpfennig\textsuperscript{1}, Daniel F. McAuley\textsuperscript{1,2}, and Rebecca J. Ingram\textsuperscript{1*}.
Supplementary Methods

Mice

All studies were approved by Queen’s University Belfast’s ethical committee and were conducted in accordance with the UK Home Office regulations. Sex- and age-(6-14 weeks) matched C57BL/6 wild-type (WT) mice and IL-17A KO mice (kindly provided by Dr Yoichiro Iwakura, Institute of Medical Science, The University of Tokyo, Japan) (1) were bred in house. Recombinase activating gene 2-deficient (Rag2 KO) mice (2) on C57BL/6 background and mice deficient in both Rag2 and the common cytokine receptor γ chain (cγ Rag2 DKO) (3) on a Balb/c background were kindly provided by Dr Mark Wilson, MRC National Institute for Medical Research, UK. Rag2 KO lack T cells but retain ILCs, in contrast cγ Rag2 DKO lack both T cell and ILCs.

Induction of lung injury in mice.

Lung injury was induced in mice by the administration of either E. coli LPS (100 µg) (Sigma, UK- serotype 0111:B4) suspended in injection grade saline, or inoculation with 5 x 10⁶ CFUs of Pseudomonas aeruginosa (PA01, kindly provided by Prof Scott Bell, Australian Infectious Diseases Research Centre). This clinically relevant bacterial pneumonia model was chosen as it induces significant levels of lung injury (4). In contrast, in the widely used CLP model, it has recently been demonstrated that lung injury is not the primary cause of mortality in the mice (5).

Mice were anaesthetised with xylazine and ketamine by intraperitoneal (i.p.) injection. Unless otherwise stated, all mice were administered LPS via the orotracheally (o.t) route. Mice were intubated using a high-pressure syringe and MicroSprayer
aerosoliser (Penn-Century. Inc. Wyndmoor, PA) (6). LPS or a saline control were delivered into the lung (50 µl). For intra-nasal (i.n) administration, 20 µl of LPS, bacteria or a saline control were applied drop wise to the animal’s nose, these were inhaled by normal respiration. Following i.n administration, animals became tachypneic, they were held in an upright position until their breathing normalised to ensure maximal delivery into the lungs. Mice were culled at 24 h post induction, unless otherwise stated. To calculate the lung indice, a measure of pulmonary inflammation (7), the following equation was used;

\[
\text{Lung index} = \frac{\text{lung weight/body weight experimental}}{\text{lung weight/body weight control}}
\]

**Lung Histology**

Lungs were excised and fixed in 10 % formaldehyde over night at room temperature for histological processing. Lung tissue was embedded in paraffin by members of the core tissue unit (CTU) in QUB and 3 µm sections were sectioned and floated onto a saline coated slide (MSC, Ireland) and dried in an oven at 60°C. The sections were de-waxed with Histoclear (National Diagnostics, US), rehydrated in decreasing concentrations of alcohol, before final transfer to distilled water for 5 minutes. Sections were stained with Haematoxylin and eosin (H&E), dried then mounted using DPX mounting media (HD Supplies, UK) and cover slips applied. DPX was allowed to solidify overnight and sections were then examined microscopically. A researcher blinded to the mouse strain/treatment group of each scored the damage to the lung in ≥ 5 field of view for each section using the system outlined by Matute-Bello et al (8).
Quantification of inflammatory markers within the lung.

BAL was obtained by the instillation of four successive 150 µL aliquots of ice cold sterile PBS into the mouse lung and the recovered fluid from each wash was pooled for each individual animal. Samples were stored on ice until cell-free supernatant was obtained by centrifugation (300 x g, 10 minutes, 4°C). For the preparation of lung homogenate, lungs were harvested and stored on ice. They were homogenised in 500 µl of sterile, ice cold PBS with a mechanical homogeniser (VWR, UK). The sample was then gently centrifuged (300 x g, 10 minutes, 4°C) to pellet the cellular material and the supernatant was collected. All samples were stored at -80°C until analysed.

ELISA was used to quantify IL-17A, IL-6, IL-23 (eBioscience, UK), keratinocyte-derived chemokine (KC), MIP-2 (Preprotech, USA); IL-2 was quantified by luminex assay (Invitrogen, UK), all following the manufacturer protocols.

Myeloperoxidase (MPO) activity was measured in the BAL fluid collected from murine in vivo experiments. MPO from human leukocytes was used to generate a standard curve (0.0625 U/mL - 0.000977 U/mL). The standards and samples were diluted (1:50) in assay buffer (potassium phosphate dibasic solution 2.5 µM). The samples were then added to a black 96-well plate (Sterilin, UK) with 50 µL of reaction cocktail (50 µM amplifu red, 20 mM hydrogen peroxide in assay buffer). The plate was incubated at room temperature in the dark for 60 minutes before measuring the fluorescence at excitation 530-570 nm and emission at 590-600 nm. All components were purchased from Sigma, UK.
Total protein concentration was measured in the BAL fluid against a standard curve of pre-determined bovine serum albumin (BSA) standards ranging from 2 mg/mL to 31.25 μg/mL (Thermo Scientific, UK) using Pierce BCA protein assay (Thermo Scientific, UK) as stated in the manufacturer’s protocol. Assays were read at 450 nm on a spectrophotometer (BioTek, U.S.A).

Isolation and preparation of lung cells
Lungs were perfused with cold sterile PBS through the right ventricle of the heart then harvested into Iscoves’s Modified Dulbecco’s Medium (IMDM) (Gibco, UK) supplemented with 10 % fetal calf serum (FCS) (Source Bioscience, UK) and 1 % penicillin/streptomycin (PAA, UK). To prepare a single-cell suspension, the lung was finely minced and incubated at 37°C in media, supplemented with 1 mg/mL Collagenase D and 200 µg/mL DNase 1 (Roche, Germany), for 1 hour with constant agitation. After incubation, the samples were passed through a 70 µm cell strainer (Becton Dickinson, UK), centrifuged (300 x g, 5 minutes, RT) and the red blood cells lysed. A live-dead cell count was then performed on the single cell suspension using a Countess automated cell counter (Invitrogen, UK).

Ex vivo cell stimulation
Single cell suspension prepared from the lungs were plated in IMDM media supplemented with 10 % FCS and 1 % P/S, and stimulated with IL-23 (50 ng/ml), IL-7 (10 ng/ml) (Milteni, UK) or IL-2 (10 ng/ml) (Dynax, USA) or combinations of these cytokines. The cells were incubated at 37°C with 5 % CO₂. At specific time points (4, 24, 48 and 72 h), the cell culture supernatant (750 μL) was removed and stored at -80°C until analysis for IL-17A by ELISA. At 72 h the cells were treated with a
commercial PMA/ionomycin based stimulation cocktail (eBioscience, UK), to restimulate IL-17 production, and protein transport inhibitor cocktail (eBioscience, UK), to prevent cellular secretion of this IL-17. After 5 h, the cells were washed and stained for analysis of intracellular IL-17, in combination with cell surface markers to identify specific cellular populations, by flow cytometry.

**Flow cytometry**

Cells were washed in FACS buffer (PBS, 2 % FCS) and the cell pellets were blocked for 15 minutes at room temperature with anti-CD16/CD32 (eBioscience, UK), then washed again. For cell surface staining cells were incubated for 30 minutes at room temperature with the antibodies against the following: Ly-6G PE, CD11b APC-efluor 660, CD4 PE-Cy7, CD8 PerCP-Cy5.5, NK1.1 PE, biotinylated anti-hematopoietic lineage panel with Streptavidin APC-efluor 780, CD3 APC-Cy7/Pacific Blue, CD8 Pacific Blue, γδ TCR APC, CD25 APC-Cy7, CD45 FITC, CD90 APC, CCR6-Alexa Fluor 647, c-KIT APC, NKp46 PE-Cy7, CD127 brilliant violet 421, Sca-1 PE and IL-23R PE. For intracellular staining, cells were surface-stained then fixed/permeabilised using the Foxp3 staining buffer set (eBioscience, UK) according to manufacturer’s instructions. Following overnight permeabilisation, antibodies targeting; RORγt PerCP-efluor 710 or IL-17A Pacific blue/ PE were used. Full details of the antibodies utilised within this study are provided in Table E1. Cells were acquired within 24 hours of staining on a FACSCanto II (Becton Dickinson, UK) and data analysed using FlowJo software (FlowJo Inc, OR, USA).
Quantitative Real Time PCR

Lung injury was induced with LPS in WT, Rag2 KO and cy Rag2 DKO mice, at 4 h the lungs collected and stored in RNAlater™ RNA Stabilisation Reagent (Qiagen, Crawley, UK) at −20°C until ready for use. Total RNA was extracted using the acid phenol method with TRIzol® (Life technologies, UK) according to the manufacturer’s protocols before resuspension in RNase-free water. Reverse transcription and quantitative PCR were conducted using the Superscript® III Platinum® One-Step Quantitative RT-PCR System kit (Life technologies, UK) following the manufacturer’s instructions. Briefly, 4 µl of extracted RNA were added in a PCR plate to 24 µl of Reaction mix containing the Taq polymerase, ROX as a reference dye and the primer/TaqMan® mix for either IL-17A or the house-keeping gene YWHAZ. The plate was briefly centrifuged and the reaction performed on a Stratagene MX3005P real-time PCR machine (Aligent Technologies, Germany) by a cycle of 15 min at 50°C and 2 min at 95°C for the reverse transcription followed by 45 cycles of 15 s at 95°C and 30 s at 60°C. Each sample was run in triplicate for both primers and a non-template control was performed. The fold change in IL-17A gene expression levels, relative to a PBS treated control, and normalised to the housekeeping gene YWHAZ, was calculated using the \(2^{-\Delta\Delta CT}\) method (9).

Statistical Analyses

Normally distributed results were compared using Student’s t-test or one-way ANOVA. Nonparametric data was normalised prior to analysis, either by log transformed analysis or arcsin transformed in the case of percentage data. The exception to this is the real-time PCR analysis in which mouse strains were
compared using a Kruskal-Wallis test. All statistical analyses were performed using Prism GraphPad software v.4.0. Graphic data represents the mean (± SEM).
References


Online supplementary figure legends

SUPPLEMENTARY TABLE E1. Details of the antibodies utilised within this study. Provided is the name, clone, conjugated fluorochrome, isotype and supplier of each all the antibodies that were utilised during this study.

SUPPLEMENTARY FIGURE E1. Flow cytometry gating strategy for determining the RORγt lymphocytic populations. Lung cells were harvested 24 h after i.t LPS. Lymphocytes within the lung were characterised. In all histograms both the antibody (black) and an isotype control (red) are shown, for RORγt+ a fluorescence minus one (light red) control was also included. Based on the cells forward and side scatter properties a lymphocyte gate was drawn. CD45 staining was used to verify these cells were leukocytes. To establish the phenotype of these RORγt+ cells populations were delineated as γδ TCR+ (γδ T cells) or Lin− (ILC3s). CD3 expression was then used to define the remaining cell populations; the CD3 positive population was then separated into CD3+ NK1.1+ (NKT cells), CD3+ CD4+ NK1.1− (CD4+ Th17 cells) or CD3+ CD8+ NK1.1− (CD8+ Tc17 cells). The CD3 negative population was used to define the CD3− NK1.1+ (NK cells).

SUPPLEMENTARY FIGURE E2; Flow cytometric gating strategy for identifying RORγt+ ILCs and phenotyping based on the expression of typical of known group 3 innate lymphoid cell populations. (A) ILCs recruited to the lung during acute lung injury were identified as being Lin−(CD3−Gr-1−CD11b−TER-11−B220−NK1.1− γδTCR−CD11c−), CD45+, RORγt+. Expression of RORγt shown in the dot plot is compared to an isotype control (red). The expression of cell surface markers (B) CD90 (alloantigen Thy-1), (C) Sca-1, (D) NKp46 (NCR), (E) CD117 (c-kit), (F) CD127
(α- chain of the receptor for IL-7), (G) CCR6. (black line) compared to isotype control (red shaded) associated with ILC3 subsets characterised (representative histograms shown). The data is representative of three independent experiments, each experiment utilised n=3 mice pooled.
<table>
<thead>
<tr>
<th>Antibody</th>
<th>Clone</th>
<th>Fluorophore</th>
<th>Isotype control</th>
<th>Supplier</th>
</tr>
</thead>
<tbody>
<tr>
<td>CD117 (Ckit)</td>
<td>2B8</td>
<td>APC</td>
<td>Rat IgG2b k</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD11b</td>
<td>M1/70</td>
<td>APC efluor 660</td>
<td>Rat IgG2b</td>
<td>eBioscience</td>
</tr>
<tr>
<td>CD127(IL-7R)</td>
<td>A7R34</td>
<td>BV421</td>
<td>Rat IgG2a k</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD196 (CCR6)</td>
<td>29-2L17</td>
<td>Alexa Fluor 647</td>
<td>Armenian Hamster IgG</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD25</td>
<td>PC61</td>
<td>APC-Cy7</td>
<td>Rat IgG1</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD3</td>
<td>17A2 ; 145-2C11</td>
<td>Pacific Blue/</td>
<td>Rat IgG2b k/ Armenian</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD4</td>
<td>GK1.5</td>
<td>PE-Cy7/ Pacific Blue</td>
<td>Rat IgG2b, k</td>
<td>eBioscience</td>
</tr>
<tr>
<td>CD45</td>
<td>30-F11</td>
<td>FITC</td>
<td>Rat IgG2b, k</td>
<td>BioLegend</td>
</tr>
<tr>
<td>CD8a</td>
<td>53-6.7</td>
<td>Pacific Blue/ PerCP-Cy5.5</td>
<td>Rat IgG2a k</td>
<td>BioLegend/ eBioscience</td>
</tr>
<tr>
<td>CD90.2</td>
<td>30-H12</td>
<td>APC</td>
<td>Rat IgG2b, k</td>
<td>BioLegend</td>
</tr>
<tr>
<td>IL-23R</td>
<td>O78-1208</td>
<td>PE</td>
<td>Rat IgG1</td>
<td>Becton Dickinson</td>
</tr>
<tr>
<td>Ly-6A/E (Sca-1)</td>
<td>D7</td>
<td>PE</td>
<td>Rat IgG2a k</td>
<td>BioLegend</td>
</tr>
<tr>
<td>Ly-6G (GR-1)</td>
<td>RB6-8C5</td>
<td>PE</td>
<td>Rat IgG2b, k</td>
<td>eBioscience</td>
</tr>
<tr>
<td>NK1.1</td>
<td>PK136</td>
<td>PE</td>
<td>Mouse IgG2a k</td>
<td>eBioscience</td>
</tr>
<tr>
<td>Nkp46 (CD335)</td>
<td>29A1.4</td>
<td>PE-Cy7</td>
<td>Rat IgG2a k</td>
<td>BioLegend</td>
</tr>
<tr>
<td>γδTCR</td>
<td>GL3</td>
<td>APC</td>
<td>Armenian Hamster IgG</td>
<td>BioLegend</td>
</tr>
<tr>
<td>Mouse</td>
<td>145-2C11, RA3-6B2, M1/70, TER-119, RB6-8C5, PK136, GL3</td>
<td>Biotin &amp; Streptavidin APC-efluor 780</td>
<td>Streptavidin only control</td>
<td>eBioscience</td>
</tr>
<tr>
<td>RORγt</td>
<td>B2D</td>
<td>PerCP-efluor 710</td>
<td>Rat IgG1 k</td>
<td>eBioscience</td>
</tr>
<tr>
<td>IL-17A</td>
<td>eBio17B7</td>
<td>Pacific blue or PE</td>
<td>Rat IgG2a k</td>
<td>eBioscience</td>
</tr>
</tbody>
</table>
Figure E1
Figure E2

A

Lineage

CD45

Rorγt

B

CD90

C

Sca-1

D

NKp46

E

c-Kit

F

CD127

G

CCR6